- Conditions
- Parkinson Disease, Idiopathic Parkinson Disease
- Interventions
- N acetyl cysteine, [F-18] Fluorodopa Positron Emission Tomography
- Dietary Supplement · Drug
- Lead sponsor
- Thomas Jefferson University
- Other
- Eligibility
- 30 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 33
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Parkinson Disease, Autonomic Nervous System Diseases, Pure Autonomic Failure
- Interventions
- 6-[18F]Fluorodopamine, 6-[18F]Fluorodopa, 13N-Ammonia
- Drug
- Lead sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
- NIH
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 89 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2023
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Parkinson Disease, Idiopathic Parkinson Disease
- Interventions
- [F-18] Fluorodopa Positron Emission Tomography, OM Meditation
- Drug · Behavioral
- Lead sponsor
- Andrew Newberg
- Other
- Eligibility
- 25 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Pheochromocytoma, Endocrine Disease, Endocrine Diseases
- Interventions
- ([18F]-DOPA), ([18F]-6F-DA)
- Drug
- Lead sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
- NIH
- Eligibility
- 3 Years to 120 Years
- Enrollment
- 3,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2048
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Congenital Hyperinsulinism, Insulinoma
- Interventions
- Fluorodopa F 18
- Drug
- Lead sponsor
- Cook Children's Health Care System
- Other
- Eligibility
- Up to 18 Years
- Enrollment
- 250 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2028
- U.S. locations
- 1
- States / cities
- Fort Worth, Texas
- Conditions
- Parkinson's Disease, Multiple System Atrophy, Autonomic Failure
- Interventions
- 13N-Ammonia, 18F-DOPA, 11C-Methylreboxetine (11C-MRB), 18F-Dopamine
- Drug
- Lead sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
- NIH
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 89 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Hyperparathyroidism, Hypercalcemia, Parathyroid Neoplasm, Multiple Endocrine Neoplasia, MEN1
- Interventions
- 68Ga-Dotatate, 18F-DOPA
- Drug
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- 2 Months and older
- Enrollment
- 1,553 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1993 – 2020
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma, Adult Anaplastic Oligodendroglioma, Adult Brain Stem Glioma, Adult Diffuse Astrocytoma, Adult Ependymoma, Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Adult Mixed Glioma, Adult Myxopapillary Ependymoma, Adult Oligodendroglioma, Adult Pilocytic Astrocytoma, Adult Pineal Gland Astrocytoma, Adult Subependymal Giant Cell Astrocytoma, Adult Subependymoma
- Interventions
- biopsy, computed tomography, therapeutic conventional surgery, radiation therapy treatment planning/simulation, radiation therapy, magnetic resonance imaging, positron emission tomography, fluorine F 18 fluorodopa
- Procedure · Radiation · Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2019
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Hyperinsulinism
- Interventions
- 18F-Fluoro Dopa PET/MRI Imaging
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- Not listed
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2030
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Glioblastoma
- Interventions
- Positron Emission Tomography, Computed Tomography, Multiparametric Magnetic Resonance Imaging Scan, Fludeoxyglucose F-18, fluorine F 18 fluorodopa
- Procedure · Radiation
- Lead sponsor
- University of Virginia
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 1
- States / cities
- Charlottesville, Virginia
- Conditions
- Glioma, Glioblastoma, Glioblastoma Multiforme
- Interventions
- FDOPA PET
- Drug
- Lead sponsor
- The Methodist Hospital Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Depression, HIV Infections, HIV-Associated Cognitive Motor Complex
- Interventions
- 18F-FDOPA, 11C-DASB
- Drug
- Lead sponsor
- National Institutes of Health Clinical Center (CC)
- NIH
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 46 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2022
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Malignant Brain Neoplasm
- Interventions
- Computed Tomography, Fluorodopa F 18, Positron Emission Tomography
- Procedure · Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Glioma, Malignant Glioma
- Interventions
- 6-[F-18]-Fluoro-L-3,4,-dihydroxyphenylalanine, PET/MRI, Surgical resection (standard of care)
- Drug · Device · Procedure
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Malignant Glioma, Recurrent Brain Neoplasm
- Interventions
- Biopsy, Computed Tomography, Diffusion Weighted Imaging, Fluorine F 18 Fluorodopa, Laboratory Biomarker Analysis, Perfusion Magnetic Resonance Imaging, Positron Emission Tomography, Therapeutic Conventional Surgery
- Procedure · Drug · Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 7 Years and older
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2024
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Congenital Hyperinsulinism (CHI), Persistent Hyperinsulinemic Hypoglycemia of Infancy (PHHI)
- Interventions
- 18 F-DOPA
- Drug
- Lead sponsor
- Children's Hospital of Philadelphia
- Other
- Eligibility
- Not listed
- Enrollment
- 130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2018
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Congenital Hyperinsulinism, Hyperinsulinism, Persistent Hyperinsulinemic Hypoglycemia of Infancy, CHI, PHHI
- Interventions
- F-DOPA, PET scan
- Drug · Radiation
- Lead sponsor
- Children's Hospital of Philadelphia
- Other
- Eligibility
- Up to 18 Years
- Enrollment
- 106 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2009
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- ACTH, Cushing's Syndrome
- Interventions
- DOTATATE PET-CT, F-DOPA PET CT, CT scan, Routine MRI scan, Gated MRI scan, 68Ga-DOTATATE, 18F-DOPA
- Radiation · Diagnostic Test · Drug
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2030
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Heathy Volunteer, Parkinsonian Syndromes, Neuroendocrine (NE) Tumors, Gliomas
- Interventions
- 18F-FDOPA
- Drug
- Lead sponsor
- Akiva Mintz
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 200 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2030
- U.S. locations
- 1
- States / cities
- Englewood, New Jersey
- Conditions
- Glioblastoma
- Interventions
- Accelerated Hypofractionated Radiation Therapy, Computed Tomography, Fluorodopa F 18, Magnetic Resonance Imaging, Positron Emission Tomography, Quality-of-Life Assessment, Questionnaire Administration, Radiation Therapy, Temozolomide, Biospecimen Collection
- Radiation · Procedure · Drug + 1 more
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 170 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 8
- States / cities
- Scottsdale, Arizona • Jacksonville, Florida • Albert Lea, Minnesota + 5 more
- Conditions
- Schizophrenia
- Interventions
- Ralmitaront, Radiolabeled PET tracer [18F]-DOPA, Placebo
- Drug · Other
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years to 50 Years · Male only
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 4
- States / cities
- Glendale, California • Torrance, California • Gaithersburg, Maryland + 1 more
- Conditions
- Cushing Syndrome, Endocrine Disease
- Interventions
- Pentetreotide, 18F-DOPA, CT scan, MRI, 18-FDG
- Drug · Device
- Lead sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
- NIH
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 95 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2019
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Congenital Hyperinsulinism (CHI), Beckwith-Wiedemann Syndrome, Insulinoma
- Interventions
- 18F-DOPA
- Drug
- Lead sponsor
- Children's Hospital of Philadelphia
- Other
- Eligibility
- Not listed
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Neuroendocrine Tumors
- Interventions
- F-18-F-DOPA
- Procedure
- Lead sponsor
- Northwell Health
- Other
- Eligibility
- 23 Years to 81 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2015
- U.S. locations
- 1
- States / cities
- Manhasset, New York